2021

B.C. heart device firm Kardium founded by Creo executives raises $115-million from Fidelity, T. Rowe Price ahead of going public

01/25/2021

Kardium's Globe Mapping and Ablation System is intended to disrupt a roughly $6-billion market for treating atrial fibrillation, which is expected to grow by 15 per cent a year as Baby Boomers age.

Read More

Kardium announces $115M in new financing for innovative atrial fibrillation treatment

01/25/2021

VANCOUVER, British Columbia – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round. The round is led by Fidelity Management & Research Company LLC., together with follow-on participation by funds and accounts advised by T. Rowe Price Associates, Inc. […]

Read More